Navigation Links
Watson Announces Limited Recall Of Fentanyl Transdermal System
Date:8/7/2009

MORRISTOWN, N.J., Aug. 7 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that one lot of 100 mcg/hr Fentanyl Transdermal System patches sold in the United States is being voluntarily recalled from wholesalers and pharmacies. The recalled patches are from Lot Number 145287A, have expiration dates of February 2011 and were manufactured by Watson Laboratories, Inc. and distributed by Watson Pharma, Inc. The affected lot of Fentanyl Transdermal System patches was shipped to customers between April 2, 2009 and May 20, 2009. No other strengths or lots were affected and the Company does not anticipate any product shortages as a result of this recall. The Company has notified the U.S. Food and Drug Administration (FDA) of the recall.

A small number of patches leaking fentanyl gel have been detected in this lot, potentially exposing patients or caregivers directly to fentanyl gel. Fentanyl patches that are leaking should not be used. No serious injuries have been reported in connection with the recalled lot. However, exposure to fentanyl gel may lead to serious adverse events, including respiratory depression and possible overdose, which may be fatal.

Anyone who has 100 mcg/hr Fentanyl Transdermal System patches should check the box or foil pouch for the lot number and expiration date to see if they have patches that are being recalled. Affected patches should not be handled directly. Anyone with 100 mcg/hr Fentanyl Transdermal System patches being recalled should call 888-345-2656, Monday through Friday, 8:00 a.m.-5:00 p.m. EDT, for instructions on how to return affected product.

Patients using fentanyl patches who have medical questions should contact their healthcare providers.

'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Watson Pharmaceuticals and Arrow Group Receive FTC Second Request
2. Watson Pharmaceuticals Receives FDA Approval for Generic Toprol XL(R) 25 MG and 50 MG
3. Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook
4. Watson Announces License Agreement With GeneraMedix for Generic Version of Ferrlecit(R)
5. Watson CFO Mark W. Durand to Take Leave of Absence
6. Watson Confirms Filing of Abbreviated New Drug Application for Generic Sanctura XR(R)
7. Watson Pharmaceuticals Receives a Complete Response Letter for Its 24-Week Formulation of TRELSTAR(R) (triptorelin pamoate) NDA from US FDA
8. Watson to Host Second Quarter 2009 Earnings Conference Call and Webcast
9. Watson Pharmaceuticals Resumes Shipment of INFeD(R) (Iron Dextran Injection, USP)
10. Watson Pharmaceuticals Receives FDA Approval for Fruit and Cinnamon Flavored Coated Nicotine Gums
11. Watson Pharmaceuticals Receives FDA Approval For Generic PLAN B(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2009)... site www.sleeping-with-a-sleeping-disorder.com is asking people ,who ... sleep aids from around the world to donate ... The submissions will be compiled in an ebook ... to be sold from the website in early ... the proceeds ,from sales of the E-book to ...
(Date:12/5/2009)... shown in a phase 1/2 clinical trial that ... of patients newly diagnosed with multiple myeloma, a cancer ... from Dana-Farber Cancer Institute. , Partial responses or better ... with the drug combination in the multi-center study, with ... in the phase 2 population, reports Paul G. Richardson, ...
(Date:12/5/2009)... Africa, December 5 The first Football,for Hope ... Town opened its doors,today (5 December 2009). FIFA ... Premier Helen Zille, 2010 FIFA World Cup Organising ... Football Association,President Kirsten Nematandani and Executive Mayor of ...
(Date:12/5/2009)... experts advise , , SATURDAY, Dec. 5 (HealthDay News) -- ... can have bad reactions to certain holiday traditions and ... wheezing, according to the American College of Allergy, Asthma ... live evergreens may choose to decorate with artificial plants, ...
(Date:12/5/2009)... today announced the launch of International Solutions, an innovative new international ... its UK equivalent. In addition to offering customers the flexibility to ... needs and budgets, International Solutions enables customers to tailor their benefits ... , ...
Breaking Medicine News(10 mins):Health News:Donate a Herbal Natural Sleep Aid to the Internet's First "Natural Sleep Aids E-book" Written by People Just Like You 2Health News:Multiple myeloma patients experience high response rate with new 3-drug combination 2Health News:Opening of First Football for Hope Centre Heralds a New Dawn for Khayelitsha 2Health News:Opening of First Football for Hope Centre Heralds a New Dawn for Khayelitsha 3Health News:Keep Asthma, Allergies at Bay for the Holidays 2Health News:AVIVA's Private Health Insurance Products Solutions Go International 2
... 8 Anpath Group, Inc.,(OTC Bulletin Board: ANPG), ... reported several advancements with,the introduction of EquineTru(R). The ... product line with the market launch of,EquineTru(R), an ... at the Atlanta Fall Classic Horse Show., ...
... MBF Healthcare,Acquisition Corp. (AMEX: MBH ), ... that it will host an investor,conference call on ... time to,discuss the recently announced signing of a ... Inc. (along with its,subsidiaries, "CHS"). Hosting the call ...
... (Nasdaq:,STXS), announced today that Bevil J. Hogg, Chief ... will present at the Deutsche Bank,Small- and Mid-Cap ... Naples,Florida on Thursday, February 14, 2008 at 2:40 ... is by invitation only. The audio,presentation will be ...
... of Breast Cancer Movement Gathers Record Attendance for Annual ... ... Susan G. Komen for the Cure(R), the,world,s largest and most ... annual Affiliate Leadership,Conference Feb. 7-9 at the Hilton Anatole in Dallas. ...
... Feb. 7 ORBIS International is,saddened to announce ... the board of,directors, the Honorable Oliver Foot. He ... ), Oliver,s dedication to reduce human ... with ORBIS, a nonprofit global development,organization that transcends ...
... in Past Three Years and Fourth Consecutive Quarterly ... Revenue Increase Over Prior Year, ... of BioZ(R) Impedance Cardiography (ICG),technology, today reported financial results for its ... and do not include,results for Vermed which was sold on August ...
Other Medicine News:Health News:Anpath Group, Inc. Announces Advancements with Animal Care Line 2Health News:Anpath Group, Inc. Announces Advancements with Animal Care Line 3Health News:MBF Healthcare Acquisition Corp. to Host Investor Conference Call to Review Stock Purchase Agreement Signed With Critical Homecare Solutions Holdings, Inc. 2Health News:MBF Healthcare Acquisition Corp. to Host Investor Conference Call to Review Stock Purchase Agreement Signed With Critical Homecare Solutions Holdings, Inc. 3Health News:MBF Healthcare Acquisition Corp. to Host Investor Conference Call to Review Stock Purchase Agreement Signed With Critical Homecare Solutions Holdings, Inc. 4Health News:Susan G. Komen for the Cure(R) Hosts Annual Affiliate Leadership Conference in Dallas 2Health News:Susan G. Komen for the Cure(R) Hosts Annual Affiliate Leadership Conference in Dallas 3Health News:ORBIS International Announces the Death of the Honorable Oliver Foot, President and Board Member 2Health News:CardioDynamics Reports Fourth Quarter and Fiscal 2007 Results with 10% Revenue Growth in 2007 2Health News:CardioDynamics Reports Fourth Quarter and Fiscal 2007 Results with 10% Revenue Growth in 2007 3Health News:CardioDynamics Reports Fourth Quarter and Fiscal 2007 Results with 10% Revenue Growth in 2007 4Health News:CardioDynamics Reports Fourth Quarter and Fiscal 2007 Results with 10% Revenue Growth in 2007 5Health News:CardioDynamics Reports Fourth Quarter and Fiscal 2007 Results with 10% Revenue Growth in 2007 6Health News:CardioDynamics Reports Fourth Quarter and Fiscal 2007 Results with 10% Revenue Growth in 2007 7
(Date:12/4/2009)... 4 Bayer Diabetes Care today announced the three grand ... Nick Jonas, of the Jonas Brothers, selected the winning video ... The grand prize is an in-person meeting today with Nick. ... like Nick, are: Caleb, age 6, from Danbury, CT, who ...
(Date:12/4/2009)... Northwest Biotherapeutics, Inc. ("NWBT" or the "Company") (OTC Bulletin ... Trademark Office has allowed its patent application on a ... manufacture of the Company,s DCVax® therapeutic cancer vaccines. ... high concentration of dendritic cells (which are the critical ...
(Date:12/4/2009)... anxiety disorder, bipolar disorder, Attention Deficit Hyperactivity Disorder ... the comorbidities reported to occur more often in ... epilepsy versus those without an epilepsy diagnosis, according ... the U.S. ,, Findings from " CNS-Related Comorbidities ...
Breaking Medicine Technology:Bayer 'Express Your Simple Win Creativity Contest' Grand Prize Winners Announced 2Bayer 'Express Your Simple Win Creativity Contest' Grand Prize Winners Announced 3Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 2Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 3Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 4Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 5Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 2Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 3TV Spotlight on DataDeed and Living Will Solutions 57725 1TV Spotlight on DataDeed and Living Will Solutions 57725 2Radiological treatment method spares patients surgery and offers 89 percent cost savings 57721 1Surgeon Battling Own Cancer Developed New Treatment 57718 1Surgeon Battling Own Cancer Developed New Treatment 57718 2Surgeon Battling Own Cancer Developed New Treatment 57718 3
... from CHARM Study in Remission at One Year ... Maintained Remission at Two ... an,open-label extension study of two Abbott pivotal studies, CHARM and ... long-term clinical remission and clinical,response, respectively, according to data presentations ...
... Alba Therapeutics Corporation,announced today that data from ... Clinical Advances in Celiac Disease session at the ... Results of the randomized,double- blind, placebo controlled study ... reactivation by gluten challenge in celiac,subjects in remission(1) ...
Other Medicine Technology:Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 2Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 3Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 4Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 5Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 6Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 7Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference 2Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference 3Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference 4Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference 5
... ergonomic chairs with concave seats and ... Select options like seats, backrests, armrests, ... chairs are recommended for the following ... static control, health care and office. ...
... Durable ergonomic chairs with concave ... support • Select options like seats, ... • Choose the BE Series for ... environments including: industry, education, laboratory, clean ...
... Durable ergonomic chairs with concave ... support • Select options like seats, ... • Choose the BE Series for ... environments including: industry, education, laboratory, clean ...
... ergonomic chairs with concave seats and ... Select options like seats, backrests, armrests, ... the BE Series for top performance ... industry, education, laboratory, clean room, static ...
Medicine Products: